“It's disappointing that none of the four have come out and shown a difference in mortality, but it does show why you need big trials,” says @JeremyFarrar.
My story on @WHO’s Solidarity trial results is out (slightly delayed by having food poisoning 🤷♂️)
Gilead's Remdesivir doesn't save lives. So says a large, multi-country study run by WHO's Solidarity trial network. An indepth look at the study by @kakape also notes that Gilead just cut a $1B deal with Europe for the drug.
“This trial doesn’t help remdesivir, that’s for sure,” says @EricTopol. “It's not a dead duck as much as hydroxychloroquine, but it certainly is not the hope that was initially signaled.”
@vkhosla No one said anything about waiting for FDA though. Just that we need proper studies before jumping to conclusions. Hydroxychloroquine fell flat after much hype. Remdesivir even received an EUA and it doesn't look too promising now (only preprint so far)
Remdesivir and interferon don't reduce COVID-19 mortality, @WHO's Solidarity trial finds. The silver lining is that the global megastudy (11,000 patients in 30 countries) worked and produced solid results fast. bit.ly/3k2zTGs by @kakape
“This trial doesn’t help remdesivir, that’s for sure,” @EricTopol says. “It's not a dead duck as much as hydroxychloroquine, but it certainly is not the hope that was initially signaled.”
Gilead knew that there were negative results for remdesivir 2 weeks before signing a US$1Bn deal with the EU
The @WHO Solidarity trial on 2743 hospitalised patients showed no effect on death or severity of #COVID19 yet @Gilead secured the cash anyway!